# A Clinical Trial of Antibody GSK1070806 in the Treatment of Patients With Moderate to Severe Crohn's Disease

> **NCT03681067** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Birmingham** · enrollment: 5 (actual)

## Conditions studied

- Crohn Disease

## Interventions

- **DRUG:** GSK1070806
- **DRUG:** Placebo- sodium chloride

## Key facts

- **NCT ID:** NCT03681067
- **Lead sponsor:** University of Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-20
- **Primary completion:** 2020-06-02
- **Final completion:** 2020-06-02
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2021-04-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03681067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03681067, "A Clinical Trial of Antibody GSK1070806 in the Treatment of Patients With Moderate to Severe Crohn's Disease". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03681067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*